LOSARTAN POTASSIUM 50MG (F-6);

EFFICACY & BIOCHEMICAL EVALUATION OF PHARMACEUTICAL OPTIMIZED WITH ESSENTIAL HYPERTENSION

Abstract

Introduction: Hypertension is one of the strongest modifiable risk factors for
cardiovascular and kidney disease and has been identified as the leading risk factor for mortality.
The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding
both protection of organs and cardiovascular mortality. It suppresses the effects of angitensin
II at its receptors, thereby blocking the rennin-angiotensin system. The rennin-angiotensin
system plays a crucial role in the control of blood pressure, and in particular it is felt to play
crucial role in hypertension. Objective: The objective of this double-blind, comparative study
evaluating efficacy and biochemical effects of optimized Losartan Potassium 50mg (F-6) as
monotherapy in adult patient with essential hypertension. Study design: Double-blind,
comparative study. Place and Duration of Study: This study was conducted at the Department
of Biochemistry, University of Karachi from January 2010 to August 2010. Methods: This was
multicenter randomized, double-blind, comparative study. Patients were randomized to receive
once Losartan Potassium 50mg (F-6) daily for 8 weeks and at the end of study efficacy and
biochemical evaluation was done. Result: The patients treated with optimized Losartan
potassium (F-6) alone, blood pressure reduction was lower, although significant; reaching values
of 140.9 ± 11.3 / m88.9 ± 5.5 mmHg (p < 0.05 versus Placebo) by the end of eight weeks of
treatment. . No significant variation of blood glucose was observed and different parameters of
lipid profile were also observed during the eight weeks of treatment with antihypertensive
regimen used. Thus, the drug regimens used may be considered neutral as regards glucose and
plasma lipid metabolism profile because drug used at low doses. Conclusions: We can suggest
that the high antihypertensive efficacy, good tolerability and no biochemical effects of the
optimized Losartan potassium (F-6) it is an excellent option for the treatment of hypertension in a
wide range of hypertensive patients, with a high potential to reduce cardiovascular risks.